Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma
Status:
Completed
Trial end date:
2015-02-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects an experimental drug, called
interleukin 21 or rIL-21, will have on malignant melanoma and whether these effects look
promising compared to dacarbazine. In addition, this study will look at the side effects of
rIL-21, and some special blood tests will be done to check the level of rIL-21 in the blood.
This study will also look at previously removed melanoma tissue to determine which patients
might benefit most from this treatment.
This research is being done because currently there is no effective treatment for this type
of cancer.